# A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

> **NCT04035005** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 1013 (actual)

## Conditions studied

- Multiple Sclerosis, Primary Progressive

## Interventions

- **DRUG:** Ocrelizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04035005
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-12
- **Primary completion:** 2025-01-15
- **Final completion:** 2028-01-19
- **Target enrollment:** 1013 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04035005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04035005, "A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04035005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*